by Melanie Venter | Sep 3, 2024 | Featured, Press
Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced... by Melanie Venter | Jun 17, 2024 | Featured, Press
Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a... by Melanie Venter | Mar 28, 2024 | Featured, Press
The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has IP and know how in vaccine... by Melanie Venter | Nov 26, 2023 | Articles, Featured
Ligand signed a purchase and sale agreement with Primrose Bio and made an investment of $15m. by Melanie Venter | Sep 19, 2023 | Articles, Featured
The cross-pollination of platforms enables the San Diego-based company to create a novel way of enhancing productivity to enable the next generation of biological therapeutics